Our results also suggest that treatment for type 2 diabetes does not always follow recommended guidelines, where new users of DPP-4i had a higher prevalence of coronary artery disease than new users SGLT2i or GLP-1 RA. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.